Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin
13 March 2015 | By Novartis
Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology...